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Abstract
Gene-environment interactions are central to the expression of obesity. The condition is strongly heritable (ie,
genetic), and most of the variation in obesity levels between countries and between individuals can be
explained by the effects of obesogenic environments on individual genetic susceptibilities. The nature of the
obesogenic environmental influences is not clear in detail, but they correlate closely with measures of
affluence. The causes of variation in genetic susceptibility are also not clearly defined, but their general nature
has become clearer. The failure of genome-wide association studies or large linkage studies to identify or
replicate causative genetic variants, together with the segregation of obesity-related traits in families,
implicates a heterogenetic mechanism in which rare, dominantly or additively expressed genetic variants are
responsible for most of common obesity. The search for rare causative variants continues with some successes,
but those identified contribute very little to the overall burden and, assuming heterogenetics, there are many
more to find. The time when genomic risk factors provide more information than do currently available
markers, such as family history, is a long way off. Genomic studies to date have contributed little, if anything,
to the prevention and treatment of common obesity and its associated disorders. This contrasts with the
obvious and immediate potential implications of the well-established overall genetic basis of obesity, which
have not yet been exploited in the clinical or public health arenas. Genomic studies, which have helped to
define the genetic basis of common obesity mainly by exclusion, will in the future play an increasingly
important role in understanding and managing obesity, but only with parallel studies of the physiological,
behavioral, and economic influences.
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Future management of human obesity: 
understanding the meaning of genetic 
susceptibility
Abstract: Gene–environment interactions are central to the expression of obesity. The condition 
is strongly heritable (ie, genetic), and most of the variation in obesity levels between countries 
and between individuals can be explained by the effects of obesogenic environments on individual 
genetic susceptibilities. The nature of the obesogenic environmental influences is not clear in 
detail, but they correlate closely with measures of affluence. The causes of variation in genetic 
susceptibility are also not clearly defined, but their general nature has become clearer. The failure 
of genome-wide association studies or large linkage studies to identify or replicate causative 
genetic variants, together with the segregation of obesity-related traits in families, implicates 
a heterogenetic mechanism in which rare, dominantly or additively expressed genetic variants 
are responsible for most of common obesity. The search for rare causative variants continues 
with some successes, but those identified contribute very little to the overall burden and, assum-
ing heterogenetics, there are many more to find. The time when genomic risk factors provide 
more information than do currently available markers, such as family history, is a long way off. 
Genomic studies to date have contributed little, if anything, to the prevention and treatment of 
common obesity and its associated disorders. This contrasts with the obvious and immediate 
potential implications of the well-established overall genetic basis of obesity, which have not 
yet been exploited in the clinical or public health arenas. Genomic studies, which have helped 
to define the genetic basis of common obesity mainly by exclusion, will in the future play an 
increasingly important role in understanding and managing obesity, but only with parallel studies 
of the physiological, behavioral, and economic influences.
Keywords: obesity phenotypes, obesogenic environment, genomics, pathophysiology, treat-
ment, prevention
Background and aims
According to the World Health Organization projections, by 2015 about 2.3 billion 
adults in the world will be overweight and over 700 million will be obese, and economic 
costing predicts that obesity-related expenditure in USA will approach US$100 billion 
per annum.1 It is now widely, if not universally, accepted that the rising national and 
global prevalence of overweight and obesity since the 1980s can be understood as the 
effects of increasingly obesogenic environments (OEs), which are correlated with mea-
sures of affluence and food availability,2 in genetically predisposed individuals.3,4
Obesity is assessed by the body mass index (BMI, kg/m2) in most epidemiological 
and genetic studies, often together with measures of central fat distribution such as waist 
circumference because of adverse metabolic and health associations. However, neither 
BMI nor other anthropometric measurements are by themselves sufficiently accurate 
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or precise as measures of body fatness in cross-sectional 
 studies.5–8 Further progress in our understanding of the 
genetic underpinnings of obesity will depend on, among other 
things, the use of more informative phenotypes.
The large number of potential proximal environmental 
factors responsible for promoting overconsumption and/or 
underexpenditure of energy and their relative importance is 
under lively debate (eg, Luke and Cooper, associated com-
mentaries, and response9), but the evidence of a primary role 
of food availability and marketing is persuasive for most.2 
Preventative public health efforts targeting food consumption 
and/or physical activity have not yet been successful10,11 and 
can appear weak against the pressure for commercial profit: 
eg, the long campaign directed at reducing consumption of 
sugar-sweetened beverages while consumption has increased 
fivefold since 1950.12 Similarly, individual weight loss pro-
grams have had very limited, if any, success as defined by 
long-term (.2 year) reduced weight maintenance.10,11,13 Past 
pharmaceutical approaches have been equally disappointing, 
both in terms of modest treatment effects and unacceptable 
side effects.14,15 At present, the most successful treatments for 
obesity are surgical procedures, still with limited application 
for most obese and overweight people.14,16
The classic twin adoption studies of Stunkard showed 
that both fatness and thinness were highly heritable and not 
influenced by the adopting family members’ adiposity.17 
Numerous genetic studies since, in a variety of populations 
and using various measures of adiposity, have been consistent 
with those fundamental findings.4 The nature of the genetic 
variation responsible for this heritability is becoming clear 
even though the particular genetic variants are not. Evidence 
of segregation of obesity-related phenotypes in families18–20 
and the failure to account for the heritability in genome-wide 
association studies (GWAS)3,21 and linkage studies22 strongly 
favor a predominant role for rare variants with large effects 
expressed under the influence of OE. The physiological 
mechanism(s) responsible has/have not been established, but 
the genetic and physiological information currently avail-
able remain consistent with the neurobehavioral hypothesis 
(NBH) proposed by O’Rahilly and Farooqi.23 In NBH, com-
mon obesity is the result of widespread genetic susceptibility 
to environmental cues related to food intake,18,24 mediated by 
appetite-regulating pathways within the hypothalamus. The 
mechanisms linking OE to the expression of obesogenic gene 
variant effects are not yet clear.
We aim here to review the recent evidence that leads us 
to accept the working model of the obesity epidemic summa-
rized above, to discuss the physiological, clinical, and public 
health implications of the model, and to discuss ways in which 
future genomic research could enhance our understanding of 
causes and potential treatments of obesity.
Obesity phenotypes have not  
been adequate in most genetic  
and genomic studies
Common obesity
We have clinical and phenotypic modeling backgrounds 
but claim no technical or theoretical expertise in genomics. 
However, we argue that the outstanding problems in the 
genetics of obesity are intimately connected with our areas 
of interest and that further progress in genomic studies is 
limited by the inadequacies of the phenotypes used in most 
studies. The choice of phenotypic markers for expensive, 
large-scale genomic studies is usually restricted to anthro-
pometric measures, BMI, and/or circumferences (waist, hip). 
Neither these measures nor the simplistic clinical manage-
ment phenotypes derived from them adequately represent the 
level of body fatness,5–8 and their continuing use contributes 
to the current uncertainties.6,25
More direct measures of body fatness based on skinfold 
thickness, bioelectric impedance analysis,26 dual-energy 
X-ray absorptiometry (DEXA), or hydrodensitometry27 have 
been used in a limited number of genomic studies without 
obvious benefits regarding gene discovery. With the more 
direct measures (skinfolds, DEXA, hydrodensitometry), 
the high cost, or other logistic requirements of phenotyping 
have restricted the applications to relatively small samples. 
While bioelectric impedance analysis is cheaper, its con-
founding by variability in hydration levels degrades its 
accuracy regarding body fat content.28,29
The concept of increased adiposity or body fatness 
appears intuitively simple but is not easy to define or mea-
sure accurately in humans. The direct measures mentioned 
earlier might provide effective approaches to measurement 
apart from their logistical problems, but even if an accurate 
measure of, eg, total fat mass is obtained, it is not clear a 
priori how to express it as a biologically meaningful index 
of increased adiposity. The common clinical usage of per-
cent body fat cutoffs is arbitrary.30 Analyzing continuous 
measures such as the percent body fat or fat mass indices 
implies assumptions about how human adiposity affects, or 
is affected by, disease processes. Using either BMI or percent 
body fat as covariates can lead to erroneous conclusions in a 
genetic context.31 One possible approach is the use of multi-
variate phenotypic constructs obtained from techniques such 
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as principal components or factor analysis, which partition 
 correlations between multiple input variables into latent 
factors. These procedures eliminate uncorrelated components 
of the input variables, which can reduce error variance and 
hence increase statistical power. Similar improvements in 
power are expected in other types of multivariate analysis 
such as structural equation modeling.32,33 Recently, we 
reported such an analysis of body composition data using 
factor analysis in a small-scale study (n∼200). We extracted 
a factor (Adiposity), which captured more precisely the seg-
regation in families of obesity-related traits than did either 
BMI or measured percent body fat.18 However, the detailed 
phenotypic characterization required for that particular analy-
sis may be impractical for large-scale genomic studies. The 
expected power benefits from multivariate phenotypes are 
most apparent when there are strong correlations between 
the individual phenotypes, as is the case with many pheno-
types obtained in genomic studies of obesity, but this is not 
the only requirement for derivation of useful phenotypes. The 
aim must be to construct biologically informative phenotypes 
which, in principle, could be achieved either by applying 
prior knowledge to the development of explicit physiologi-
cal models composed of measurable variables31 or by careful 
consideration of the biological and statistical properties of the 
available raw phenotypes.18 It is also important to consider 
the origins of the correlations between phenotypic markers, 
so as to specify the correct functional forms of the relation-
ships, and especially to avoid correlated errors when choosing 
phenotypes for inclusion. For example, in our own study,18 
which used a combination of anthropometric and DEXA 
measurements, we used log-transformations to accommo-
date the dimensional relationships between input variables 
and avoided inclusion of multiple phenotypes based on the 
same primary measurement (eg, fat mass and percent fat) and 
therefore sharing correlated errors. These precautions, which 
amount to standard requirements for the extraction of reliable 
multivariate constructs, have generally not been applied in 
multivariate genomic or genetic studies.20,34
The choice of phenotype(s) for genomic studies of com-
mon obesity is unresolved. If, as we discuss in the follow-
ing sections, the potential utility of large-scale association 
studies has been exhausted, more expensive phenotypic 
measures may be justified in smaller scale case–control or 
linkage studies. It seems likely to us that any single pheno-
typic measure would contain less genetic information than 
carefully designed multivariate constructs. For example, 
multivariate constructs derived from commonly obtained 
anthropometric measurements (weight, height, and, waist–hip 
 circumferences) may be worth considering. However, we 
expect that the additional costs of direct measures of body 
fat would be more than repaid by the increased power and 
interpretability of the resulting analyses.
Sub-obesity phenotypes
Clinically, obesity and/or overweight are not homogeneous 
phenotypes. There are prospects for identifying useful genetic 
markers for those at greater or lesser risk of adverse health 
consequences of obesity, which would assist in developing 
or targeting treatments. There is growing evidence that a 
substantial subset of obese individuals (∼25%), defined by a 
lack of risk factors for comorbidities, may be protected from 
some or all of the adverse consequences of obesity.35 There 
is an established association between abdominal, especially 
visceral, fat deposition and adverse health consequences at 
least partly independent of total adiposity, which may be 
under independent genetic influences.36,37 Identification of 
genetic determinants of these clinical phenotypes, we sub-
mit, depends on the development of genetically informative 
quantitative phenotypes using the principles summarized 
earlier.
There are no effective nonsurgical 
treatments or preventative 
strategies for obesity
Despite much nutritional and physical activity research, no 
lifestyle regimen has been reported to maintain substantial 
weight loss in the long term.38 This result is consistent with 
the strong feedback of metabolic and appetite-regulating 
hormones to the hypothalamus when weight loss does occur 
in the obese,39 a finding consistent with the predictions of the 
NBH. Similarly, public health initiatives promoting lifestyle 
changes at the population level have been minimally, if at 
all, effective in reducing obesity levels.11 There is almost 
no other area in drug development that is replete with as 
many failures and withdrawals as seen in obesity.40  Current 
novel obesity agents include a 5HT2c receptor agonist 
(Lorcaserin), a combination of phentermine and extended-
release topiramate (Qysmia), both of which have modest 
treatment effects and side effects of concern to regulatory 
agencies41 and a peripherally acting drug  (Beloranib, a 
methionine aminopeptidase inhibitor) currently in Phase III 
trials, so far without major side effects.42 Of those three, 
only Beloranib offers a prospect of broad usage, but to 
date, results of treatment have only been reported out to 
12 weeks. Currently, only bariatric surgery achieves long-
term weight loss: by physical restriction (banding), by 





increasing gastrointestinal satiety hormone release (gastric 
bypass), and/or by diverting nutrients.43,44
Despite this lack of effective treatments and strategies, 
some governments are being advised to consider financial 
penalties for obese patients in regard to health insurance, 
justified by the belief that obesity is a personal choice.45 
In the USA, the National Institutes of Health has funded 
the Childhood Obesity Prevention and Treatment Research 
(COPTR) consortium formed to prevent obesity in preschool-
ers and treat obesity in 1,700 13–17 year olds.46 Reports of 
recent childhood lifestyle interventions in randomized trials 
showed no significant weight effect despite employing the 
currently regarded optimum methodology.47 For example, 
12-month follow-up of shared care management in 3–10 year 
olds in a randomized trial showed no better BMI outcomes 
for intervention than untreated controls (intervention effect 
−0.1 [−0.7, 0.5] kg/m2).48 Against this background of failure, 
the possible emotional impact of frequent measurements 
of body size and weight of a child (and mother)49,50 should 
not be ignored when considering large-scale projects such 
as COPTR.46 It is also not possible at present to determine 
which young people are “healthy” obese, and arguably, who 
do not require medical intervention for improved metabolic 
health.35 In summary, the treatment issue in obesity is the lack 
of proven long-term effective treatments at both the individual 
and population levels.
Genetic variants contributing to 
common obesity are expressed 
under obesogenic environmental 
influences
Gene–environment interactions are central to the expres-
sion of obesity. The rapid rise in prevalence in developed 
countries over the last three decades, coupled with the strong 
heritability of obesity, allows no other conclusion.51 Obesity 
rates continue to rise in developing countries, but are at or 
near saturation in developed countries.52,53 While the identity 
and strengths of the proximal factors comprising OE are not 
agreed upon, it is clear that indices of affluence either within 
(eg, socioeconomic status [SES]) or between (eg, gross 
domestic product [GDP]) populations can be powerful proxies 
for total OE.54–58 The effect of OE by those measures on obesity 
levels is not linear, with evidence of saturation in developed in 
developed countries56 consistent with reports of diminishing 
national trends in some developed countries. The apparent 
plateau level of national BMI at high GDP (∼26 kg/m2)56 
is well below a notional full expression of clinically defined 
obesity (BMI$30 kg/m2), indicating that substantially 
,100% of individuals are susceptible to OE. Within 
countries, the situation is more complex.54,55 In multiple 
samples from 36 developing countries, a positive effect of 
individual SES explained 74% of the within-country variance 
in BMI,58 but in developed countries the relationship is often 
reversed, with low SES groups showing the highest obesity 
prevalence.54,55 The reasons for this apparent reversal of effect 
are not clear. Likely contributors include the influence edu-
cational level on obesogenic behaviors and negative effects 
of obesity on SES.59 There are also methodological issues 
regarding confounding variables, particularly associations 
between measures of SES and ethnicity. However, in the 
most extensively studied, if not necessarily representative, 
country60 (USA), the association between one measure of 
SES (education) and BMI has weakened over the period 
1970–2000.61 It may be that SES now plays a more minor 
role compared to the national level of affluence in the most 
developed countries.
Measures of affluence explain approximately 50% of 
the between-country variance in BMI and approximately 
70% of the within-country BMI variance in developing 
countries.58 No gene-discovery studies (GWAS or linkage 
or candidate) that we are aware of have utilized any markers 
of OE as covariates. Omitting such a powerful conditional 
determinant from genetic studies, perhaps unavoidable with 
the uncertainties of identity and measurement, must lead to 
a reduced power to detect genetic associations and to arti-
factual associations if population stratification, either within 
or between countries, leads to confounding between OE and 
genetic markers.
The mechanistic link(s) at the molecular level between 
OE and obesity development are not clear. The physiological 
evidence implicates hypothalamic appetite-regulating path-
ways with their various sensor and effector systems,23,24 and 
the genomic evidence (see “Obesogenic genetic variants”) 
still supports the basic structure of the NBH. In this scheme, 
reduced (or increased) function in various components leads 
to either an increased drive to eat in the presence of OE 
and/or, equivalently, a decreased restraint of an appropriate 
drive in response to feedback signals. In either case, without 
counteracting changes in energy expenditure, the expected 
result is maintenance of larger fat stores at a level that either 
balances the increased drive with higher feedback signals 
or normalizes the feedback signal itself in the dysfunctional 
pathway or parallel (redundant) pathways.
There is currently great interest in the possibility that epi-
genetic changes to gene function could provide a molecular 
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link between OE and obesogenic gene variant effects. This 
proposed mechanism is a key element in the hypothesis of 
the developmental origins of health and disease (DOHaD), 
which proposes that a substantial fraction of the rising preva-
lence of obesity (and other complex diseases) is due to expo-
sures to OE in utero.62,63 Environmental conditions, including 
nutrient availability, can epigenetically influence expression 
of genes involved in energy metabolism64,65 and at least one 
component of NBH (proopiomelanocortin [POMC]66) in 
humans. Epigenetic DNA methylation may be enriched and 
more variable in obese compared to nonobese humans.67 
These and many other studies, predominantly in animal 
models, have clearly established the potential of DOHaD, but 
much less evidence exists of any substantial contribution to 
endemic human obesity. Direct evidence in humans comes 
from studies of the effects of maternal obesity on offspring 
phenotypes, studies of which are very difficult to design with 
appropriate controls; most do not account for the genetic 
influences on obesity which will confound any effects of 
in utero environment. The strongest human evidence is in 
a series of studies of the effects of maternal bariatric sur-
gery on obesity in children, using a within-subject design 
(pre- and post-surgery) to control for genetic influences. 
Children conceived after surgery had substantially lower 
levels of various obesity-related phenotypes compared to 
those conceived before surgery68 and showed an altered 
DNA methylation pattern in white blood cells.69 However, 
there are reasons to doubt that these findings are applicable 
to endemic obesity. Both studies used morbidly obese sub-
jects (BMI ≈46 kg/m2) undergoing the most drastic form of 
bariatric surgery (biliopancreatic diversion) which resulted 
in massive weight loss (BMI ≈30 kg/m2), which itself results 
in nutritional deficiencies in utero.70 The incidence of folate 
deficiency is a particular concern for the interpretation of 
the DNA methylation pattern.62 In contrast, a large hospital-
records-based within-subject study of the effects of much 
less severe, purely restrictive bariatric surgery (BMI change 
from 36 kg/m2 to 32 kg/m2) found no evidence for reduced 
adiposity in children conceived after surgery, with trends 
in the opposite direction.71 Other studies were designed to 
isolate any nongenetic effect of maternal adiposity by use 
of maternal FTO genotype as an instrumental variable72 or 
by comparing influences of maternal and paternal adiposity 
on offspring adiposity.73 Both studies concluded that any 
maternal effect on offspring adiposity is weak and unlikely 
to explain any substantial fraction of the obesity epidemic. 
So while DOHaD and its proposed epigenetic mechanisms 
are based on undoubtedly exciting emerging biological 
insights, we found no persuasive evidence for an important 
role of DOHaD in endemic human obesity.
Heritability and mode of inheritance  
of obesity susceptibility
Obesity is highly heritable, but estimates of the degree 
of heritability have varied substantially between studies 
(h2∼40%–80%). The source(s) of this variability have not 
been established, but a leading candidate is the effects of 
variations and trends in OE. For example, twin studies gener-
ally give higher heritability estimates than do sibling studies 
or multigenerational family studies, perhaps because OE is 
likely to vary less between twins than between generations or 
siblings of different ages.19 Similarly, as obesity levels have 
risen over time in response to rising OE, so have the measured 
genetic contributions to the overall variance, and hence h2.74 
Many studies have detected evidence of segregation and/or 
multimodality of adiposity-related traits but the implied 
modes of inheritance have varied. Early studies (reviewed 
in Price et al19) found evidence of recessive expression of 
higher adiposity, while more recent studies have tended to 
favor dominant or additive models of expression.18–20 As 
argued by Price et al,19 part of this variation may be due to 
secular trends in gene–OE interactions,74 which have the 
effect of simulating recessive inheritance in multigenerational 
studies. The use of extreme obesity phenotypes would also 
tend to favor a recessive pattern if the true mode is addi-
tive and the heterozygous phenotype is either obscured by 
definition75 or is indistinguishable in the data.76,77 The use of 
inappropriate phenotypes can also obscure signals of domi-
nance or additivity. Our own demonstration of segregation of 
 Adiposity in families with type 2 diabetes mellitus (T2DM)18 
was obtained only with a multivariate phenotype based on 
direct measures of body compartments (Figure 1A), and 
was obscured in body fat percent and BMI data (Figure 1B), 
despite the close correlations between Adiposity and body fat 
percent or BMI (R2=0.87, Figure 1C). The genetic informa-
tion is contained within the apparent noise in Figure 1C. In 
summary, published studies are either not inconsistent with, 
or give explicit support to, dominant or additive expression 
of genetic susceptibility to increased adiposity. Because of 
its use of an informative and biologically plausible pheno-
type and a highly enriched sample (family history positive 
compared to a carefully matched family history negative 
control group) from a developed (OE-saturated) country, and 
despite its small sample size (n=202), we submit our study18 
as the best current indicator of the mode of inheritance of 
susceptibility to common obesity.
















































Figure 1 Distributions of age- and sex-adjusted obesity-related phenotypes in 
healthy adults with a family history of T2DM (FH+, n=80).
Notes: (A) A latent factor (Adiposity) derived by rotated factor analysis of body 
composition and anthropometric data. (B) Residual log-transformed BMi (Adiposity 
and loge BMi are both presented as residuals from age and sex models). Data were 
binned by deciles of the full sample (FH+, FH−, n=202) and fitted to a bimodal normal 
distribution. The dashed line in (A) represents the fitted distribution of Adiposity 
(no fit was obtained in the loge BMi data). The segregation of Adiposity in FH+ is 
consistent with dominant expression of rare risk variants with major effects, which 
are expressed in over half of FH+ and which can account for most of the T2DM-
associated obesity in this population. (C) Relationship between Adiposity and BMi 
in healthy individuals with or without a family history of T2DM (n=202).18 The line 
represents the fit of Adiposity to log-transformed BMI (r2=0.87). Reproduced from 
Jenkins AB, Batterham M, Samocha-Bonet D, Tonks K, Greenfield JR, Campbell LV. 
Segregation of a latent high Adiposity phenotype in families with a history of type 
2 diabetes mellitus implicates rare obesity-susceptibility genetic variants with large 
effects in diabetes-related obesity. PLoS One. 2013;8:e70435.18
Abbreviations: T2DM, type 2 diabetes mellitus; BMi, body mass index.





The bimodal distribution of Adiposity in individuals 
with a positive family history of T2DM (FH+, Figure 1A) is 
consistent with segregation in families of rare obesity suscep-
tibility variants with major effects, contrary to the predictions 
of a polygenic model in which variants at many loci have 
cumulative, small effects on the phenotype.  Previous stud-
ies of the transmission of obesity-related phenotypes have 
also generally not favored the polygenic model. However, 
a recent simulation study based on extensive identity by 
descent and BMI data in families reaches the conclusion 
that polygenic inheritance of BMI is capable of explaining 
the failure of replication of hits in linkage studies, possibly 
by random sampling of chromosomal blocks containing 
multiple obesogenic variants of small effects, and therefore 
questions the conclusion that a heterogenetic model is favored 
by the exclusion of competing hypotheses.78 Their conclu-
sion is based on the equivalence of various polygenetic and 
heterogenetic models, rather than on statistical evidence 
favoring any particular model. They prefer the polygenic 
model for reasons of parsimony, although it seems to us the 
least parsimonious of their mechanisms. The heterogenetic 
models tested were very stringently defined in terms of 
private variants in each family, ie, a minor allele fraction 
(MAF) of ∼0.01% vide the usual definition of rare (MAF 
,1%) based on the current power of GWAS.79 Whether the 
result could apply to more realistic situations in which, for 
example, interactions between genes and environment were 
considered and the heterogenetic model was less stringently 
defined is not yet clear, and we take the current evidence for 
segregation of obesity-related phenotypes to strongly favor 
the heterogenetic model.
Our analysis18 was insensitive to the nature of the inher-
ited obesogenic variants, but we can conclude that they are 
rare to have escaped detection in large-scale studies even 
of BMI, even allowing for confounding by OE, and must 
have large effects to account for the separation between 
modes of Adiposity (0.93 standard deviation units [SD]). 
The two factors extracted by Tayo et al,20 which are likely to 
partition the variance in Adiposity, show similar effect sizes 
(0.84–0.89 SD). The BMI equivalent of the effect size in 
Adiposity is approximately 4 kg/m2, and other segregation 
studies have reported similarly large effects although direct 
comparisons are hindered by the variety of phenotypes 
analyzed (BMI,19 fat mass,80 percent body fat,81 skinfolds82), 
the different populations sampled, and the genetic models 
tested (additive, dominant, mixed). Our major effects 
accounted for 91% for the age- and sex-adjusted Adiposity 
variance, but this high value is a function of the enrichment 
of susceptibility in our sample (positive family history) as 
well as the high national GDP and hence OE. The residual 
variance (9%; 95% CI, 4%–69%) contains the effects of 
all other determinants of Adiposity including polygenes, 
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the environment, and interactions between them. While 
the point estimate indicates minimal contribution from all 
these sources in our sample, the wide confidence intervals 
(probably related to small sample size) do not rule out a 
substantial contribution in this or other samples. However, 
taken with the other estimates of heritability of obesity-
related phenotypes and their strengths and limitations 
referred to above, our result supports a predominant role 
of segregating rare variants in the transmission of obesity 
susceptibility.
Obesogenic genetic variants
The genetic determinants responsible for endemic obesity 
remain largely undiscovered. Over 50 loci have been asso-
ciated with BMI and/or categorical obesity in GWAS and 
meta-analyses,3,21,83 but the combined (additive) effects of 
all variants account for only a small fraction of the pheno-
typic variation (1%–2%), leaving most of the heritability 
unexplained. Possible sources of this missing heritability 
have been well discussed by Hebebrand et al25: nonspecific 
phenotypes, measurement error, small effects sizes, rare 
variants, inflated heritability estimates, developmental 
aspects, gene–gene and gene–environment interactions, to 
which we add common copy number variations (CNVs). 
While GWAS have not systematically targeted CNVs, 
a recent study of linkage disequilibrium between common 
single nucleotide variants (SNVs) and common CNVs con-
cluded that “[...] for complex traits, the heritability void left 
by genome-wide association studies will not be accounted 
for by common CNVs.”84 While all of those sources of error 
no doubt contribute to the current heritability void, the 
evidence of segregation of obesity-related traits points to a 
predominant role of rare variants or a heterogenetic model 
of transmission. Under a heterogenetic model, estimates 
of heritability are not a useful way of combining evidence 
from gene-discovery studies, and it is more instructive 
to examine the effect sizes attributable to identified gene 
variants. Figure 2 illustrates the distribution of effect sizes 
(when reported in or readily transformable to BMI units, 
n=47); GWAS-identified results are extracted from recent 
reviews3,21,83 or the studies referred to therein. The sources 
of the effect sizes of other variants identified in various 
candidate designs are discussed in points “1. FTO” to 
“7. 16p11.2”. Compared to our estimates of the segregating 
effect size (4.1 kg/m2),18 most effects, including all identi-
fied in GWAS, are vanishingly small and can be ruled out as 
contributors to segregation, although they, and other similar 
but unknown loci, presumably contribute to the background 
variability. The exclusions should include FTO variants if 
based on effect size alone, but as we discuss in “1. FTO”, 
their emerging mechanism of action may provide a model 
for other larger effects in the same region. Also, most GWAS 
effects on BMI are so small that there can be no confidence 
that they represent effects on body fat as opposed nonfat 
compartments. That leaves only the outliers in Figure 2 as 
candidates for the types of variant that could contribute to 
a segregation signal.
1. FTO: common single-nucleotide polymorphisms (SNPs) 
in the FTO region have the largest effect size of any vari-
ants detected in GWAS, but that effect (0.4 kg/m2) is too 
small to make a significant contribution to the segregation 
signal that we and others detect. However, it may be that 
other rarer variants in the same region could contribute, 
and recent advances regarding the mechanisms of action 
of the FTO variants provide a model that exemplifies 
the potential of the NBH. Obesity-associated sequences 
within FTO are functionally connected through noncod-
ing RNA with an increased expression of the homeobox 
gene IRX3, deletion of which results in reduced fat mass 
in mice.85 Studies in humans have found associations 
between obesity-associated FTO variants and levels of the 
satiety hormone leptin (negative),86 the hunger hormone 
ghrelin (positive),86,87 and brain responsivity to food cues 
(positive).87 So while common FTO SNPs do not contribute 
substantially to common obesity susceptibility, they do 
illustrate the potential of other rarer variants affecting the 
same processes.
2. AMY1: CNVs in AMY1 encoding salivary amylase have 
been associated with variations in BMI (low copy num-
ber associated with higher BMI) in two independent 
samples.88 The effect size plotted in Figure 2 (0.75 kg/m2) 
is based on the maximum possible negative difference in 
copy number (−5) from the mean of the normal-weight 
distributions in Falchi et al.88 This effect size is small 







Figure 2 Boxplot of published heterozygote effect sizes (when reported in or 
transformable to BMi units) of obesity-associated genetic variants (n=47).
Notes: The box represents the median and interquartile range and the whiskers 
extend to 1.5 times the interquartile range. The box and whiskers enclose all variants 
identified in genome-wide association studies except FTO. The red arrow indicates the 
BMi effect size calculated from our study of the segregation of Adiposity.18
Abbreviations: BMi, body mass index; POMC, proopiomelanocortin.





segregation signal in larger scale studies. The CNV in 
AMY1 was investigated in relation to BMI after an initial 
screen of effects on gene expression in adipose tissue,88 
but the salivary amylase product is also expressed in saliva 
under the influence of copy number89 and in various other 
tissues. The mechanisms linking AMY1 expression and 
BMI have not been established, but AMY1 is known to 
have a role in sensory perception of starch in foods as 
well as being regulated by autonomic nervous system 
(ANS) activity,90 providing potential links to and from 
hypothalamic appetite-regulating centers and therefore 
possible consistency with the NBH.
3. SIM1: SIM1 is a homologue of a transcription factor in 
mice, which is known to be involved in the development 
of hypothalamic appetite regulation centers, and haplo-
insufficiency results in a hyperphagic obesity in mice 
and humans. Common SNPs in and near SIM1 regions 
were associated with BMI in a candidate gene study in 
Pima Indians.91 The risk alleles were common in Pima 
Indians (∼0.6), but less so in Europeans (∼0.3) with no 
association with BMI in the European sample. Perhaps 
linked functional variants have originated in or become 
enriched (through genetic drift or selection) in Pima 
Indians. The potential mechanism is clear, and consistent 
with the NBH, and the effect size (2.2 kg/m2) would be 
detectable in a reasonably powered linkage study.
4. CTNNBL1: multiple SNPs mainly in intronic regions of 
CTNNBL1 were associated with BMI and fat mass in a 
sample of unrelated US Caucasians and were supported 
in a French Caucasian case–control study of categorical 
obesity,92 but not in a central European sample93 or a  Danish 
sample.94 Failure of replication is an expected feature of 
a heterogenetic model in which different populations or 
smaller groups (down to families) could be expected to 
have different genetic origins of obesity susceptibility. The 
effect size of 2.7 kg/m2 would be detectable in a reasonably 
powered linkage study, but there are reasons to doubt the 
specificity of the continuous phenotypes for body fatness. 
Liu et al92 used directly measured fat mass as a control on 
the BMI analyses, but did not control for effects of body 
size on fat mass, and so both phenotypes contain informa-
tion about nonfat body compartments. Consistent with this 
potential confounding, the replication study by Andreasen 
et al94 found no association with BMI, but significant asso-
ciations with weight and height. CTNNBL1 variants may be 
associated with increased risk of obesity, but the measured 
effect size on BMI includes an unknown but probably 
substantial contribution from genetic effects on body size. 
Confirmation using an unbiased phenotype is needed. The 
functions of CTNNBL1 are not established, and there is no 
clear potential link to the NBH, but it is expressed in at least 
one region of the human central nervous system (CNS) 
(cortex) and variants have been associated with measures 
of CNS function (memory).95
5. POMC: POMC is a complex pro-peptide, the products of 
which are secreted by neurons that are critically involved 
in appetite regulation. Congenital deficiency of POMC is 
the cause of a rare form of monogenic obesity, and haplo-
insufficiency of POMC is linked to increased BMI in 
affected families.96 The effects of POMC deficiency were 
important elements in the development of the NBH.23 
The heterozygote effect size in Figure 2 (3.7 kg/m2) is 
an approximation based the original report in SD units 
(+1.3) multiplied by the average SD in males and females 
(2.85 kg/m2) in the reference data97 used by Farooqi 
et al.96
6. LEP and LEPR: leptin acting through the leptin receptor 
functions as a feedback signal from adipose tissue fat 
stores with strong suppressive effects on appetite through 
the hypothalamic leptin–melanocortin signaling pathway. 
Both homozygous leptin and leptin receptor deficiencies 
cause rare monogenic severe obesity in humans driven 
by hyperphagia, and both are crucial elements in the 
development of the NBH. Heterozygous loss-of-function 
variants in both genes are associated with substantial 
effects on body fatness.98,99 In both cases, the phenotype 
affected was directly measured by body fat percent 
adjusted for age, sex, height, and weight, and the effects 
were substantial: +20% body fat for LEP98 and +6% for 
LEPR,99 which roughly translate to effects in BMI units 
in our sample18 of +9 and +3 kg/m2, respectively.
7. 16p11.2: independent associations with obesity of large 
deletions at two locations in 16p11.2 have been detected 
following a strategy of resequencing at loci known to be 
associated with rare forms of extreme obesity,100,101 and 
one of the locations was replicated using continuous 
BMI in a population sample101 represented in Figure 2. 
The BMI effect size in Figure 2 is based on a very small 
sample (4) of heterozygous carriers in that one popula-
tion, but the combined effect on BMI in all populations 
sampled was +1.1 SD units (n=8), similar to our effect 
size on Adiposity (+0.93 SD).18 The responsible causal 
loci are not clear, but the deleted region contains SH2B1, 
which has established links to hyperphagia and obesity 
in humans and animals acting through leptin signaling 
pathways102 consistent with the NBH.
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As judged by effect size, only the POMC, LEP, and LEPR 
heterozygous loss-of-function mutations and the deletions at 
16p11.2 stand out as possible examples of the types of variants 
which could contribute to a heterogenetic mechanism of sus-
ceptibility to common obesity, although contributions from the 
others cannot be excluded (except perhaps CTNNBL1). While 
we do not suppose that the outlier loci identified in Figure 2 
are necessarily representative of all causative variants, it is 
noteworthy that their mean effect size (+3.9 kg/m2) is very 
close to our estimate of average effect size (+4.1 kg/m2).18 The 
gene products of the first three have key roles in appetite regu-
lation, as does one candidate for the 16p11.2 effect, and as do 
other gene products identified as causative agents in severe 
monogenic obesity (PSK1, MC4R, SIM1).21 Other causes 
of severe (syndromic) obesity associated with generalized 
developmental CNS disturbances are also linked to disruption 
of appetite regulation (Bardet–Biedl syndrome, Prader–Willi 
syndrome, pseudohypoparathyroidism, WAGR syndrome).21 
When taken together with our evidence of increased sensi-
tivity to food-related cues in healthy family-history-positive 
individuals,24 the genomic evidence continues to point to 
hypothalamic appetite regulation pathways as the most likely 
location of rare variants driving the susceptibility to obesity in 
response to increased OE as proposed in the NBH. The effects 
of common variants in FTO illustrate how such mechanisms 
can operate, and have increased interest in the potential roles 
of noncoding RNAs.
The search for rare variants with large effects on obe-
sity susceptibility is in progress and has resulted in some 
success,101 as have related approaches in other complex 
diseases.103,104 However, the contributions of the newly iden-
tified variants to population susceptibilities are very small, 
and if, as we conclude, most of the obesity susceptibility 
is due to rare variants, there are many more to find. There 
are formidable problems in design and statistical analysis 
to be solved before identification of rare variants becomes 
a routine procedure, and we may currently be able to find 
only the “low-hanging fruit” that are amenable to current 
techniques.101 The variants’ effects must be large, and it 
might therefore be hoped that simple phenotypes such as 
BMI would be adequate for reliable discovery, more so than 
in GWAS where the small effect sizes must be interpreted 
with caution due to biases in BMI. However, even large 
effects can be generated or obscured by BMI bias; measured 
biases in different ethnic groups range from −6 kg/m2 to 
+4.5 kg/m2 at equivalent body fat percentage105,106 and in our 
ethnically unselected sample from −3.6 kg/m2 to +6.7 kg/m2 
(95% CI −3.1, 4.3) at equivalent Adiposity (Figure 1C).18 
There is a clear need for more informative phenotypes in 
these studies.
Implications of a heterogenetic 
mechanism for gene discovery, 
treatment, and prevention
GwAS studies have reached  
their potential
The results obtained from GWAS studies have excluded a 
major causative role for common genetic variants in obesity, 
directly for common SNPs and indirectly for common 
CNVs.84 The GWAS design does not have the power to detect 
rare causative variants in any feasible sample size. Power and 
accuracy would undoubtedly be improved by the use of better 
phenotypes than BMI, but it is unlikely that the improve-
ments would be enough to capture many rare variants. The 
increased costs associated with better phenotyping would be 
better used in smaller scale studies following the types of 
approaches recommended by Walters et al.101
Many variants may produce similar  
effects on obesity-related traits
Under a heterogenetic model, the separation between modes 
of Adiposity in Figure 1A represents the average effect size 
of the causative variants. Our analysis treats it as a fixed (ie, 
constant) effect, and while we were unable to model the range 
of dispersion of effects, nor any heterogeneity of background 
variability, the data are consistent with a very narrow range 
of effect sizes superimposed on a constant background vari-
ability. It might be thought implausible that many hetero-
genetic variants could all result in similar effects sizes, but 
it is possible for that pattern to arise from the properties of 
the affected physiological system(s). For example, the NBH 
proposes that appetite regulation systems in the hypothalamus 
are the target of most obesogenic variants; those systems are 
very complex involving a large number of sensory, effector, 
and integrative processes, all interacting with and subject to 
feedback from other central regulatory systems such as the 
ANS, and affected by systems modulating mood and other 
behavioral traits. The overall properties of this system, or 
network, of sensors, integrators, and effectors are not clearly 
understood, but it is likely that it exhibits features of redun-
dancy in that a complete or partial failure of any component 
is partly compensated for by the remaining intact links (an 
analogy can be found in the properties of the glucoregula-
tory system107). Such a system could produce the segregation 
behavior that we and others observe.





Can phenotypic convergence help  
to locate new therapeutic targets?
Under some possible structures of the physiological system(s) 
involved, there could be clustering of the effects of multiple 
variants on potentially targetable subsystems. However, 
appetite regulation is such a central process with links to 
and from many other systems (ANS, mood, etc) that it makes 
specific targeting without undesirable side effects potentially 
very difficult, as can been seen in the history of drug devel-
opment in this area.40 Recent interest in the melanocortin-4 
receptor as a potentially targetable component of the NBH 
appears to be an illustration of continuing problems of this 
nature. Antagonist compounds to melanocortin-4 receptor 
are being developed for targeting depression and anxiety,108 
while agonists are being developed to target obesity.109 This is 
reminiscent of the history of Rimonabant, a drug developed 
to target obesity though antagonism of cannabinoid recep-
tors in satiety pathways but which was withdrawn due to 
side effects on depression.40 An improved understanding of 
the properties of the appetite-regulating system as a control 
system could affect strategies for targeting. If, for example, 
the system is strongly hierarchical with lateral connections 
to other systems such as the ANS mainly at high levels in the 
hierarchy, that could be quite different in its implications from 
a more distributed network-like structure with many lateral 
connections. If a hierarchical structure could be defined, 
there may be obvious potential targets at the mid-level in the 
system, below the lateral links. A network structure presents 
a much more challenging problem.
Similarities and differences in  
obesity susceptibility in populations
Obesity and overweight vary between populations due to 
effects of and interactions between genetic and environ-
mental factors. Some small genetically isolated populations 
have developed very high prevalences of obesity in response 
to recent environmental changes (eg, Pima Indians,110 
Nauruans,111 Australian Aboriginals112). There are also 
marked, though usually less extreme, differences in obesity 
prevalences between large national populations,113 which, 
as discussed earlier, can be assigned mainly to the effects of 
OE on genetically susceptible individuals. The genetic deter-
minants of the variation in susceptibility between individuals 
or groups are not clear, except for a very small number of 
individuals with severe monogenic obesity. There are cur-
rently no known genetic variants or combinations of variants 
that are helpful as indicators of risk, in either individuals or 
populations. Genetic risk scores calculated by adding known 
obesogenic variant loads have minimal predictive power.114 
A very rough calculation based on current estimates of effect 
sizes (Figure 2) indicates that approximately 40 different vari-
ants per individual would be needed to account for obesity 
risk using a multiplicative (epistatic) model.
The origin of the undefined heterogenetic variation 
responsible for the varying phenotypic responses to OE is 
also unclear. Plausible theories include the effects of posi-
tive or negative selection, or of genetic drift, the pros and 
cons of which have been extensively discussed115–117 without 
resolution. A strong case can be made for selection, which 
brings together many features of obesity.117 The need for 
Homo sapiens to supply adequate glucose for a large brain to 
metabolize in recurrent famine situations and for the female 
to store sufficient fat to carry a pregnancy successfully and 
feed the baby could have ensured selection of genes that 
prioritized high-energy nutrients in the sparse environments 
and encouraged rapid ingestion and fat storage. It would be 
interesting to know whether the CNV in the salivary amylase 
gene (AMY1), which affects detection of starch and associ-
ates with higher BMI, has been subject to pre-agricultural 
selection. Parallel selection for rapid immune and stress 
responsiveness is also possible.117 Those “survivor” genes 
selected as a result of responsiveness to environmental nutri-
ent cues could, with current OE, be predicted to increase 
the prevalence of obesity. However, there is at present very 
little direct evidence from genomic studies which bears on 
this question. A few studies report signals of selection at 
obesity susceptibility loci identified in GWAS118,119 but no 
clear pattern has yet emerged. If however, as we conclude, 
causative obesogenic variants are rare, unknown, and not 
captured in GWAS, the detected selection signals have mar-
ginal relevance to endemic obesity and we do not yet have 
the genomic data to test selection hypotheses.
Opportunity for more targeted 
prevention and customized 
treatment of obesity
The results of genomic studies to date have contributed very 
little, if anything of immediate relevance to the prevention 
and treatment of common obesity and its associated disorders. 
This contrasts, in our view, with the obvious and immediate 
potential implications of the well-established genetic basis for 
the disorder, which have not yet been exploited in the clinical 
or public health arenas. It seems to us that the failure, to date, 
to explain obesity susceptibility by genomic studies is, in some 
quarters, being interpreted incorrectly as questioning the over-
all genetic basis of the disorder. It may be that accumulation of 
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causal variants would therefore amplify the genetic message, 
but the time when risk information from genomic data would 
be more informative than, say, family history appears to be a 
long way off. Similarly, we can find no evidence that known 
genomic markers are able to predict responses to currently 
available treatments. Again, this contrasts with the potential for 
known nongenomic risk factors, like family history, to predict 
the need for and responses to interventions.120
In the future, it is probable that information from genomic 
and physiological studies will identify new therapeutic targets 
that ideally would avoid the side effects responsible for the 
recurrent failure of drug development.40 In the short term, dis-
covery of genomic markers that would help to identify subsets 
of patients who would either respond to currently available 
treatments or who are at greater or lesser risk of the common 
side effects or comorbidities of obesity would be an advance. 
A recent analysis found that the benefit of reduced availability 
of junk food in schools was restricted to children with a family 
history of overweight.120 This highlights one of the potential 
benefits of genetic risk classification of individuals, but there 
is much to do before genomic information provides better risk 
prediction than do currently available markers such as fam-
ily history. A family history of T2DM may be a particularly 
powerful discriminator as it identifies a group with history of 
obesity with pathogenic consequences.18,24
There is strong desire in many quarters to intervene early, 
in children or in utero, in part because childhood obesity is a 
strong predictor of adult obesity and its consequences. As we 
now understand, this relationship reflects the shared genetic 
makeup of child and adult and is unlikely to be causative. The 
drive for aggressive early interventions ought to be dimin-
ished by the knowledge of the genetic basis of the disorder 
and by the lack of effectiveness of past interventions and the 
potential adverse consequences of interventions.49,50
Implications for enhanced patient 
care such as quality of life
An acceptance by science, medicine, and the public that 
common obesity is strongly heritable would in itself be a 
therapeutic advance, which should lead to significant changes 
to current approaches:
•	 Development of a more sympathetic approach to current 
patient management by clinicians who would then accept 
that genetic predisposition to susceptibility to the current 
OE underlies the repeated failures of “will-power”.121
•	 Lessening of repetitive weight loss attempts undertaken 
despite the inevitable regain and the personal sense of 
failure that this entails.
•	 Early life intervention should be undertaken only where 
evidence of both benefit and lack of harm has been 
demonstrated in studies. There is a real possibility of 
permanent mental and physical harm if useless interven-
tions are repeated in ever younger populations.49,50
•	 Similarly, public health interventions to prevent obesity 
that are unsuccessful must be altered or abandoned. The 
public influences on obesity are mainly in the domains 
of economics and marketing, not in modifiable per-
sonal behaviors. Investment in ineffective behavioral 
messages targeting obesity is futile and serves only to 
maintain a false picture of the problem ignoring the 
genetic element, and thereby maintaining the dominant 
public51 and clinical121 view of obesity as a personal 
failing.
Studies to define the condition of healthy obesity and 
its maintenance will allow less intervention, and hence 
increased quality of life, if no adverse associations or health 
conditions are found. There are no established protective 
markers yet, but a recent report of a low-frequency (1.5%) 
variant in the Cyclin D2 gene, which increases body mass 
but decreases diabetes risk, may be an encouraging sign122; 
1.5% could represent a useful proportion of the healthy 
obese (∼25%).
Conclusion
As genomic naïves, it appears to us that in the immediate 
future we must aim or hope for two things:
1. Identification of points of convergence in phenotypic 
pathways by better measurement and assessment of col-
lateral links to other physiological systems. We should 
not aim to personalize treatments to an individual gene, 
which seems very unrealistic in this domain, and should 
be targeting the effects of groups of genes by satiety 
induction.
2. Identification, discrimination, and quantitation of obe-
sogenic environmental factors and understanding how 
they interact with obesogenic genetic variants to increase 
their effect. There may be opportunities to counteract 
personal exposures to elements of OE or to identify more 
realistic targets for public health interventions.
We believe that genomic studies, which have helped to 
define the genetic basis of common obesity mainly by exclu-
sion, will in the future play an increasingly important role 
in the understanding and management of obesity, but not 
without parallel studies of the physiological, behavioral, and 
economic influences, and especially not without the use of 
more informative phenotypes than BMI.
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